Cernilton, a standardized pollen extract, is known to have an antiinflammatory capacity and therefore in this study only patients with an inflammatory phenotype were included. An infectious phenotype was excluded by antibiotic
pretreatment before baseline. Compared to placebo, Cernilton significantly improved total symptoms, pain and quality of life in patients with inflammatory CP-CPPS without severe side effects. Up to date there exists no standardized treatment for this very prevalent condition. This study was able to show that in a specific patient cohort, namely patients with inflammatory CP-CPPS, a pollen-extract might be a useful treatment option.